PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2&#945; phosphorylation in established cell lines and primary human leukemia cells.

Yeomans, Alison; Lemm, Elizabeth; Wilmore, Sarah; Cavell, Breeze E; Valle-Argos, Beatriz; Krysov, Sergey; Hidalgo, Marina Sanchez; Leonard, Elodie; Willis, Anne E; Forconi, Francesco; Stevenson, Freda K; Steele, Andrew J; Coldwell, Mark J; Packham, Graham

PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2α phosphorylation in established cell lines and primary human leukemia cells.

Yeomans, Alison; Lemm, Elizabeth; Wilmore, Sarah; Cavell, Breeze E; Valle-Argos, Beatriz; Krysov, Sergey; Hidalgo, Marina Sanchez; Leonard, Elodie; Willis, Anne E; Forconi, Francesco; Stevenson, Freda K; Steele, Andrew J; Coldwell, Mark J; Packham, Graham.

Afiliação

Yeomans A; Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Southampton, UK.
Lemm E; Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Southampton, UK.
Wilmore S; Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Southampton, UK.
Cavell BE; Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Southampton, UK.
Valle-Argos B; Current Address: Public Health England, Porton Down, Salisbury, UK.
Krysov S; Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Southampton, UK.
Hidalgo MS; Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Southampton, UK.
Leonard E; Current Address: Bart's Cancer Institute, Queen Mary University of London, London, UK.
Willis AE; Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Southampton, UK.
Forconi F; Current Address: Department of Pharmacology, Faculty of Pharmacy, University of Seville, Seville, Spain.
Stevenson FK; Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Southampton, UK.
Steele AJ; Current Address: XPE Pharma and Science, Wavre, Belgium.
Coldwell MJ; MRC Toxicology Unit, Leicester, UK.
Packham G; Haematology Oncology Group, Cancer Sciences Unit, Cancer Research UK Centre, University of Southampton, Faculty of Medicine, Southampton, UK.

Oncotarget ; 7(46): 74807-74819, 2016 11 15.

Article em En | MEDLINE | ID: mdl-27579538

Assuntos

Fator de Iniciação 2 em Eucariotos/metabolismo; Isotiocianatos/farmacologia; Leucemia/genética; Leucemia/metabolismo; Alvo Mecanístico do Complexo 1 de Rapamicina/metabolismo; Biossíntese de Proteínas/efeitos dos fármacos; Anticorpos Anti-Idiotípicos/farmacologia; Linhagem Celular Tumoral; Sobrevivência Celular/efeitos dos fármacos; Relação Dose-Resposta a Droga; Regulação Leucêmica da Expressão Gênica/efeitos dos fármacos; Genes myc; Humanos; Leucemia Linfocítica Crônica de Células B/genética; Leucemia Linfocítica Crônica de Células B/metabolismo; Células MCF-7; Fosforilação/efeitos dos fármacos; RNA Mensageiro/genética; Receptores de Antígenos de Linfócitos B/metabolismo; Estresse Fisiológico; Transcrição Gênica/efeitos dos fármacos

Palavras-chave

MYC; eIF2α; mRNA translation; mTORC1; phenethylisothiocyanate

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biossíntese de Proteínas / Leucemia / Fator de Iniciação 2 em Eucariotos / Isotiocianatos / Alvo Mecanístico do Complexo 1 de Rapamicina Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Oncotarget Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Reino Unido País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google